Jazz Pharmaceuticals plc (JAZZ) Cash Flow Statement

The gap between net income and operating cash flow is the central signal in this dataset, and it is driven almost entirely by non-cash amortization of acquired intangibles and stock-based compensation of roughly $60M to $80M per quarter. Operating cash flow was positive in every reported quarter, which indicates the underlying product portfolio continues to convert revenue into cash even when GAAP earnings are negative. Investors should monitor whether this conversion holds once amortization charges normalize, since the OCF-to-net-income ratio is not a meaningful metric in quarters where net income turns negative.

The 2025Q2 trough at 9.6% coincided with a sharp working capital outflow and a large reported loss, suggesting that quarterly cash generation is sensitive to rebate accruals and payment timing rather than to steady operating momentum. Recent quarters have stabilized in a 33% to 39% band, which is a healthier profile for a company carrying significant debt. Whether this level is sustainable depends on gross-to-net pressure from payers, which the reported figures do not directly isolate.

Low capex intensity is consistent with a specialty pharmaceutical company that outsources most manufacturing and relies on intangible assets rather than plant and equipment. The relevant reinvestment question is therefore not capital expenditure but the cash cost of R&D and commercial spending, which runs well above capex. The rise in capex to 3.4% and 4.0% of revenue in late 2025 may reflect facility or systems investment, but the data does not specify its purpose.

The magnitude of these swings relative to operating cash flow suggests that accrued rebates, returns, and receivable timing are material to reported cash generation. Inflows that follow large outflows point to timing effects rather than structural improvement, which argues against extrapolating any single strong quarter. The pattern warrants monitoring of receivable collection and rebate accrual trends to judge whether the business is managing payer mix or simply shifting cash between periods.

The two large acquisition outflows exceed a full year of free cash flow at the reported run rate, which indicates that deployment has been dominated by inorganic investment rather than shareholder returns or debt reduction. The absence of dividends is consistent with a company prioritizing deleveraging and acquisition integration. Whether these acquisitions earn a return above the cost of the debt used to fund them is not determinable from the supplied data and warrants further investigation.

Summing the disclosed figures, operating cash flow has been consistently positive while net income has swung between large losses and modest profits, a pattern that indicates the accounting earnings base is burdened by non-cash charges rather than weak underlying economics. This divergence is favorable on a cash basis but should not be read as proof of earnings power, because amortization of acquired intangibles reflects real past capital spent. The long-run question is whether the product portfolio can sustain cash generation as those intangibles are written down over time.